Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	65.49	47.64	38.35	62.9	54.69
Revenue Growth (YoY)	37.48%	24.22%	-39.03%	15.00%	59.73%
Cost of Revenue	22.98	19.59	16.35	10.87	10.9
Gross Profit	42.51	28.05	22	52.03	43.8
Selling, General & Admin	14.96	11.71	12.73	11.15	9.9
Research & Development	17.09	29.35	29.73	38.17	44.62
Operating Expenses	32.05	41.06	42.46	49.32	54.52
Operating Income	10.46	-13.01	-20.46	2.71	-10.72
Interest Expense / Income	1.89	1.38	7.12	9.23	7.56
Pretax Income	8.57	-14.4	-27.58	-6.52	-18.28
Income Tax	0.25	0.53	0	0	0
Net Income	8.31	-14.93	-27.58	-6.52	-18.28
Shares Outstanding (Basic)	68	48	44	29	15
Shares Outstanding (Diluted)	82	48	44	29	15
Shares Change	70.04%	9.81%	51.43%	96.44%	0.85%
EPS (Basic)	0.12	-0.31	-0.62	-0.22	-1.23
EPS (Diluted)	0.09	-0.31	-0.62	-0.22	-1.23
Free Cash Flow	-2.47	-25.63	-11.69	-26.76	-19.99
Free Cash Flow Per Share	-0.04	-0.53	-0.27	-0.92	-1.35
Gross Margin	64.91%	58.87%	57.37%	82.71%	80.08%
Operating Margin	15.97%	-27.32%	-53.36%	4.31%	-19.59%
Profit Margin	12.69%	-31.33%	-71.92%	-10.37%	-33.42%
Free Cash Flow Margin	-3.77%	-53.80%	-30.49%	-42.55%	-36.54%
Effective Tax Rate	2.97%	-	-	-	-
EBITDA	11.65	-11.93	-19.34	4.01	-9.1
EBITDA Margin	17.79%	-25.04%	-50.44%	6.38%	-16.64%
Depreciation & Amortization	1.19	1.09	1.12	1.3	1.62
EBIT	10.46	-13.01	-20.46	2.71	-10.72
EBIT Margin	15.97%	-27.32%	-53.36%	4.31%	-19.59%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).